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Clinical evidence shows that in males obesity is frequently associated with hypogonadism and vice versa; also, low testosterone
levels have been considered a “hallmark” of metabolic syndrome in men. These observations indicate that there is a strict
connection between anatomically and functionally distinct cell types such as white adipocytes and Leydig cells, that synthesize
testosterone. Adipose tissue is able to control several functions of the testis through its products secreted in the bloodstream.
On the other hand, circulating levels of testosterone and estradiol deeply aﬀect adipocyte proliferation, diﬀerentiation, and fat
mass distribution, hereby controlling critical metabolic functions, such as food intake, insulin sensitivity, vascular reactivity,
and immunity. This paper highlights the existing clinical and experimental evidence linking androgens and adipose tissue and
illustrates the consequences occurring when the balance between fat mass distribution and eugonadism is lost.
1.Introduction
Adipose tissue, in addition to its role as a storage for triglyc-
erides, can be considered as an active, atypical endocrine
organ [1], given its ability to synthesize and secrete into
the bloodstream several hormones. Overall, only thirty
percentofadiposetissueisrepresentedbymatureadipocytes,
given that multiple cell types are present in its contest.
In fact, the remaining tissue is represented by multipotent
stem cells, nerve tissue, small blood vessels, ﬁbroblasts, and
preadipocytes in various stages of diﬀerentiation [2]. Impor-
tantly,adiposetissuecontributestoregulateseveralfunctions
such as energy balance, food intake and appetite, immunity,
insulin sensitivity, blood pressure and reproduction [3],
releasing adipokines that have both local and systemic
biological eﬀects. Dysfunctional secretion of adipokines
and free fatty acids contributes to the development of an
inﬂammatory state and has a causal role for the development
of the insulin-resistant state of obesity [4].
Two types of adipose tissue are present in mammals:
white adipose tissue (WAT) and brown adipose tissue (BAT).
WAT stores energy as triglycerides. In case of lack of energy,
such as fasting, lipolysis in WAT causes the release of fatty
acids into the plasma to provide fuel for energy generation.
Indeed lipases contained in adipocytes transform triglyc-
erides into fatty acid and glycerol that are transported via the
blood to the muscle, liver, and BAT to fatty acids oxidation
[5]. In contrast, BAT plays a physiological function in
adaptive thermogenesis storing triglycerides in multilocular
adipocytes that serve as energy reserves easily accessible to
heat production and restore energy expenditure induced by
cold exposure or diet [6].
Also adipose tissue is distributed unevenly through the
body and is represented by two major compartments which
are diﬀerent for distribution and metabolism: subcutaneous
and visceral depots [7]. Intra-abdominal or visceral fat
induces an increased risk of cardiovascular and metabolic
complications, whereas subcutaneous fat exerts some still2 International Journal of Endocrinology
undeﬁned protective actions [8]. Visceral and subcutaneous
adipose tissues express diﬀerent adipokines. An important
role in the pathogenesis of cardiovascular diseases is played
by visceral fat, since it expresses many substances strongly
involved in cardiovascular diseases, such as leptin, TNFα,I L -
6,PAI-1,whichhaveadirectaccesstotheliverviaportalvein,
with a strong impact on the inﬂammatory processes [9].
Subcutaneous fat is metabolically less active than visceral
fat and produces mostly protective substances such as leptin
and adiponectin [10] and is less sensitive to glucocorticoids
because it has lower levels of glucocorticoid receptor [11–
13], thereby it could exert a protective role on metabolic
homeostasis, hence counteracting the dysfunctional adipose
tissue in visceral and ectopic compartments [14].
Aim ofthis paperis to reviewthe most recentclinical and
experimental evidence linking androgens and adipose tissue
and to discuss the reciprocal interplay between obesity and
hypogonadism.
2.LeptinandTesticular Function
The discovery of leptin in 1994 opened an exciting ﬁeld of
intense research, focused on the endocrine function of the
adipocyte, and conferred to adipose tissue the attribution of
anendocrineorgan.Leptinisapleiotropiccytokine-likehor-
mone that is involved in the regulation of energy homeosta-
sis, neuroendocrine function, immunity, lipid and glucose
homeostasis, and fatty acid oxidation [15, 16]. Importantly,
in normal condition, circulating levels of leptin are positively
correlated with adiposity [17]. On the other hand, leptin-
deﬁcient mice carrying an homozigous mutation disrupting
leptin gene (ob/ob mice) are hyperphagic, show lower energy
expenditureatrest,andarelessactive,andthenshowasevere
form of obesity [18] due to the lack of leptin signalling to the
brain. Of course in such condition, leptin levels are virtually
absent and do not correlate with fat mass. Furthermore,
ob/ob mice are sterile and have an abnormal spermatogenesis
because of an insuﬃcient hypothalamic-pituitary drive with
consequent low circulating gonadal steroids [19, 20]. Leptin
treatment normalizes body weight and restore reproduction
capacity in ob/ob males [20]. Interestingly, it has been shown
that obesity per se is not the cause of infertility in leptin
deﬁciencybecausecaloricrestrictiondoesnotrestorefertility
in the ob/ob mouse. This suggests that leptin is directly
related to the modiﬁcations of reproductive capacity [21].
In line with these studies, in humans, endogenous leptin
absence is associated with hypogonadism and absence of
pubertal development [22, 23]. Moreover, a mutation in the
db gene that encodes leptin receptor (Ob-R) leads to the syn-
thesis of truncated leptin receptor that lacks the intracellular
domain [24]. The db/db mouse has an alterated reproductive
function similar to those of the ob/ob mouse, but given that
thedefectisatthereceptorlevel,leptintreatmentisunableto
either restore fertility or modify the appetite of these animals
[25]. Hoggard et al. ﬁrst identiﬁed, by in situ hybridization,
the expression of Ob-R in the spermatic cells and Leydig
cells [26]. It has been shown that leptin enters the testis by
a passive, nonsaturable process [27]. A large body of evi-
dence indicates that leptin modulates the paracrine network
[28, 29] that controls gonadotropin-stimulated testicular
steroidogenesis [30]. Immunohistochemical studies demon-
stratedthatmousetestisgermcellsexpressafunctionalOb-R
capable of signal transduction [31]. These data suggest that
leptin can mediate proliferation and diﬀerentiation of germ
cells and then might be locally involved in the pathogenesis
of infertility observed in leptin-deﬁcient mice [31]. In a
recent study, a group of proapoptotic-related genes, that
may play an important role in mediating the increased germ
cell apoptosis and impaired sperm production, has been
identiﬁed within the testes of leptin-deﬁcient mice [32]. This
study suggests a fundamental role of leptin signalling within
the test is in the control of spermatogenesis.
On the other hand, excess of leptin has a negative impact
on Leydig cells function [28]. In fact, treatment of cultured
rat Leydig cells with leptin strongly inhibits hCG stimu-
lated testosterone production in a dose-dependent manner.
Importantly, this eﬀect occurs at concentrations within the
range of circulating levels in obese men [25]. Disruption
of steroidogenic pathway occurs at the level of 17–20 lyase,
as shown by the concomitant accumulation of metabolites
upstream of this enzymatic step [28]. Obese patients have
reduced androgen concentrations, and this reduction is
related to the increase of fat mass [33] and leptin levels
[34]. Moreover, the androgen response to human chorionic
gonadotropin (hCG) stimulation is impaired in obese men,
and leptin is the best hormonal predictor of reduction to
androgen response related to obesity [35]. On the other
hand, no association between leptin and dihydrotestosterone
circulating levels has been observed [36].
These observations suggest that leptin excess might
have an important role in the hypogonadism, frequently
observed in obese men, through a direct inhibition of Leydig
cell steroidogenesis [25]. We have hypothesized that leptin
acts through diﬀerent sites and that there are diﬀerent
concentration thresholds for distinct eﬀects of leptin on
reproduction [25]; thus, a narrow range of circulating
concentration of leptin are necessary in order to maintain
a physiological reproductive function, and concentrations
below or above these thresholds have a negative impact
on hypothalamus-pituitary axis (lower threshold), or upon
Leydig cell steroidogenesis (higher threshold).
3.Androgens,FatMetabolism, and
AdiposeBiology
Testosterone is the major circulating androgen and is present
in plasma as free or unbound testosterone, albumin-bound,
and sex hormone-binding globulin [SHBG]-bound. In lean
men, about 50% of testosterone is bound to albumin
and other proteins, 44% is bound to SHBG, and 2% is
unbound [37]. The biologically active component that is
readily available to the tissues (bioavailable testosterone) is
the proportion of unbound testosterone together with the
albumin-bound fraction. A study showed that bioavailable
testosterone is positively related to muscle strength and total
body bone mineral density and negatively related to fat mass
in healthy elderly men [38]. The fraction of testosterone
bound to SHBG in serum is proportional to the SHBG levels.International Journal of Endocrinology 3
SHBG production in the liver is regulated by several factors
and hormones, and its levels are increased by estrogen and
downregulated by obesity and insulin resistance conditions
[39].
Androgens inﬂuence gene transcription through the
activation of the androgen receptor (AR), a ligand-activated
transcription factor that binds speciﬁc DNA motifs in
i t st a r g e tg e n e s[ 40]. The extension of the polymorphic
polyglutamine (CAG repeat number) of the exon 1 of the AR
modulates androgen eﬀects: androgen-induced target activi-
ties are attenuated according to the length of triplet residues
[41]. Such polymorphism can inﬂuence the activity and
the expression of AR and plasma androgen concentration,
directly contributing to the prevalence of central adiposity
[42, 43]. In particular, the CAG repeat polymorphism
in the androgen receptor gene could modulate body fat
mass and serum concentrations of leptin and insulin in
men through a direct eﬀect upon adipocyte sensitivity to
androgens. Phenotypic eﬀects on body fat mass could be
explained by estrogen action more than androgen action,
because of the increased estrogen/androgen ratio in the
presence of higher CAG length; in fact, in a normal
functioning adult hypothalamic—pituitary—gonadal axis, a
reduced testosterone feedback, in case of a long AR CAG
repeat, is compensated by increased androgen production,
becauseof increased LHstimulation, withsubsequenthigher
conversion to estrogens [44].
Testosterone can act directly or be converted to the
more potent androgen 5-dihydrotestosterone (DHT) by 5α-
reductase or to estrogens by aromatase (ARO) [45, 46].
ARO activity has been detected in adipose tissue [47], and
several studies have demonstrated a potentially important
role for this enzyme in obesity, central fat accumulation, and
metabolicsyndrome(MetS)[48],throughestrogenreceptors
(ERs) and ARs, which are abundantly expressed in the
adipocyte and share related functions to suppress adipose
tissue accumulation and improve insulin sensitivity [49].
In a recent study, a marked decline in serum leptin levels
after short-term aromatase inhibition in healthy young and
elderly men has been observed [50].
A line of evidence has been reported that strongly
suggests the involvement of estrogen in lipid metabolism
in the adipose tissue. Fat mass is increased in male mice
withhomozygousinactivationofeithertheestrogenreceptor
gene or aromatase gene, and estrogen replacement is able
to restore normal conditions in these models [51, 52]. At
a molecular level, it has been shown that estrogens sup-
press fat accumulation and lipoprotein lipase (LPL, a key
regulating enzyme for energy metabolism, catabolizing pla-
sma triglycerides into free fatty acids and glycerol) mRNA
expression in 3T3-L1 cells stably expressing the ER.
Obesity is associated with physiological changes which
include important modiﬁcations in circulating sex steroids
levels. In particular, obese men show increased plasma
levels of estrogens and decreased bioavailable levels of
androgens. This is due to an increase in ARO activity that
mediates peripheral conversion of androgens to estrogens
[53]. Circulating values of total testosterone should not be
lower than 8nmol/L (230ng/dL). Values below this cut-oﬀ
are associated with severe impairments of body composition
and glucose metabolism [54–57].
Finally, adipose tissue is able to aﬀect gonadotropin
release by the pituitary, both directly, through increased
secretion of cytokines, in particular TNFa [58], or indirectly,
by increased conversion of circulating androgens into estro-
gens, which are known to decrease LH pulse [59].
4. Hypogonadism andMetabolicSyndrome:
ClinicalEvidence
Excess visceral fat and related comorbidities deﬁne a con-
dition named metabolic syndrome, characterized by hyper-
tension, obesity, dyslipidemia, type 2 diabetes, and insulin
resistance [60, 61].
It is well established that testosterone deﬁciency fre-
quently results in loss of libido and erectile dysfunction,
which can be easily restored by androgen replacement ther-
apy. Moreover, androgens directly or indirectly aﬀect every
body compartment outside reproductive organs including
body composition, bone density, physical and cognitive fun-
ction [62].
Patients with testosterone levels below 8nmol/L (230ng/
dL) beneﬁt from testosterone replacement, and testosterone
administration is considered if total serum testosterone
level is between 8 and 12nmol/L, and symptoms and
signssuggestiveoftestosteronedeﬁciency(obesity,hyperten-
sion, dyslipidemia, insulin resistance, erectile dysfunction,
decreased muscle mass and strength, decreased bone mineral
density, and depressed mood) are present [63].
In recent years, several lines of evidence focused on the
frequent association of hypogonadism, obesity, and MetS.
Patients with MetS show signiﬁcantly lower testosterone
plasma levels in comparison with healthy individual [54–
57, 64, 65]. Furthermore, MetS is associated with low
testosterone levels independently from the criteria applied,
supporting the concept that MetS can be considered as
an independent risk factor for male hypogonadism [66].
In addition, prospective studies have demonstrated that
low testosterone levels predict the development of diabetes
and MetS [67–69]. In this context, low plasma levels of
testosterone and SHBG may be early markers of MetS in
nonobese men, providing a warning sign in normal weight
men, considered at lower risk of developing MetS [67–69].
On the other hand, low testosterone levels could con-
tribute to the accumulation of excess fat, establishing a
vicious cycle. In fact, hypogonadism is known to induce
(a) a muscle mass reduction and visceral fat mass increase,
(b) insulin resistance, and (c) an increase of the activity of
lipoprotein lipase (LPL), the main enzymatic regulator of
triglyceride uptake in the fat cell, preferentially in abdominal
fat [62].
Interesting studies evaluated body composition changes
in men undergoing androgen deprivation therapy for non-
metastatic prostate cancer. 12 and 48 weeks of androgen
deprivation determined a signiﬁcant increase of BMI and
fat mass [70] and an increased incidence of diabetes and
cardiovascular disease [71].4 International Journal of Endocrinology
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Figure 1: Eﬀect of testosterone on 3T3-L1 adipose diﬀerentiation. Red oil staining of mature 3T3-L1 adipocytes (scale bar, 70μm) (Caprio
M.etal.,unpublished),classicallydiﬀerentiatedintheabsence(left)orinthepresence(right)of10￿7 Mtestosterone.Testosteronetreatment
determines a marked reduction in size and number of lipid droplets, in accordance with previous reports [73].
Rapid weight loss with successful weight maintenance in
obese men with MetS induced a sustained increase in free
testosteronelevels[72].Also,testosteronetreatmentofobese,
insulin-resistant, nondiabetic and diabetic men has been
shown to reduce fat mass, increase lean body mass, decrease
waist circumference, which represents a valid parameter of
thedegreeofvisceralobesity,ﬁnallyimprovingHOMAindex
and glycemic control [58, 66].
The frequent association of hypogonadism and obesity
has led a group of experts to formulate the following rec-
ommendation: patients with clinical conditions associated
withinsulinresistance(obesity,type2diabetes,MetS)should
be screened for testosterone deﬁciency, given that such
conditions often coexist [63].
5. Effects of Low Testosterone Levels on
BodyFatMass
As shown in the previous paragraph, several lines of
evidence strongly suggest that androgens inﬂuence body fat
distribution and accumulation (see Figure 1). Men aﬀected
by androgen resistance due to gene inactivation of the AR
show high visceral fat [43]. Male mice lacking AR develop
obesity with increased lipogenesis in WAT and liver [74, 75].
In males, the antiobesity action of testosterone might be
indirectly mediated via AR signalling in skeletal muscle. In
fact, testosterone promotes the commitment of pluripotent
cells of mesenchymal origin into myogenic lineage in vitro,
by inhibiting adipogenic diﬀerentiation. These eﬀects are
mediated through an AR-dependent mechanism [76]. The
same authors a few years later demonstrated that in 3T3-
L1 preadipocytes, AR modulates adipogenic diﬀerentiation
by directly activating downstream Wnt eﬀector molecules,
including β-catenin, T-cell factor (TCF), and lymphoid-
enhancer factor (LEF) [73] (see Figure 1).
Recently, we have demonstrated that Drospirenone
(DRSP), a progestogen with a modest antiandrogenic activ-
ity, widely used for contraception [77–79], strongly inhibits
adipose diﬀerentiation both in murine (3T3-L1) as well as
in human preadipocytes ex vivo. It is important to remark
that DRSP is a powerful antagonist of the mineralocorticoid
receptor (MR), which is a pivotal factor for the induction
of adipogenesis. We have shown that the antiadipogenic
eﬀect of DRSP relies on speciﬁc antagonism on the MR
[80]. Surprisingly, DRSP antiadipogenic eﬀect is blunted in
presence of testosterone, whereas we could have predicted
as y n e r g i ce ﬀect on the inhibition of adipogenesis. In order
to explain these data, we hypothesize that chronic treatment
of preadipocytes in vitro with testosterone could upregulate
AR, as already shown in diﬀerent cellular models [81, 82].
As a consequence, increased levels of AR may bind DRSP as
an AR antagonist, and the overall availability of DRSP as an
anti-MR could result reduced.
ARactivationinskeletalmusclemightindirectlydecrease
WAT mass through increased muscle oxidative metabolism
or through the release of an unknown circulating factor [49].
Indeed,inmusclecellsoftransgenicmaleratsoverexpressing
AR, increased lean mass with hypertrophy of type IIb ﬁbers,
increasedoxidativemetabolism,anddecreasedadipocytesize
and WAT mass are observed [83]. However, adipose-speciﬁc
AR knockout mice are not obese and show increased WAT
production of leptin without leptin resistance [84]. Authors
conclude that in adipocytes AR plays an inhibitory role in
leptin production [84], but lack of androgens signalling in
the adipocyte is not suﬃcient to promote obesity. Probably,
theadipocyteisnottheonlyplayerinthecomplexregulation
of fat metabolism, and other cell types in its context could
represent important targets of androgens. Tissue-speciﬁc
inactivation of AR is deemed necessary to clarify these
aspects.
6. FuturePerspectivesand Conclusions
Experimental and clinical studies indicate that adipose tissue
and gonads communicate and inﬂuence each other, either
directly or indirectly, through several circulating factors (see
Figures 2(a) and 2(b)). Obesity is often associated with
lowplasma-testosteronelevelsandreproductivedysfunction,International Journal of Endocrinology 5
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Figure 2: Reciprocal interplay between white adipose tissue (WAT)
and testis. (a) In normal conditions, circulating androgens control
adipocyte size and adipose mass. On the other hand, plasmatic lep-
tin, mainly produced by adipose tissue, regulate testicular steroido-
genesis. Dashed bars indicate the reciprocal interplay between
testis (through androgens) and adipose tissue (mainly through
leptin). (b) Androgen deﬁciency induces expansion of fat mass and
subsequent dysregulation of several functions controlled by adipose
tissue such as insulin sensitivity, blood pressure, vascular reactivity,
and immunity. The state of insulin resistance determined by obesity
leads to reduced production of SHBG. The consequent reduction
in testosterone triggers expansion of adipose mass with subsequent
increase in aromatase (ARO) activity, which in turn mediates
peripheral conversion of testosterone to estradiol. Increased estro-
gen levels induce a reduction of LH pulse which contributes
to the reduction in androgen production. On the other hand,
excess of circulating leptin, due to increased adipose mass, disrupts
testicularsteroidogenesis,withconsequentsuppressionofandrogen
production. The vicious cycle is triggered. AR: androgen receptor.
given that low testosterone may not be necessarily observed
in human obesity, nor be the only cause of visceral obesity.
This can be due to excessive circulating levels of leptin,
whichhavebeenshowntodisruptthesteroidogenicfunction
of Leydig cell, with a subsequent reduction in hCG-driven
testosterone production. Other adipokines, together with
leptin, could play a direct or indirect role in the alteration
of Leydig cell function in obesity.
On the other hand, circulating levels of sex hormones
control fat mass distribution and expansion, mainly through
activation of estrogen and androgen receptors in adipose
tissue. Of interest, a recent work highlighted the profound
impact of testosterone on cardiovascular function improving
functional capacity, heart rate, muscle strength, and glucose
metabolism in elderly patients with coronary heart failure
[85]. We hypothesize that the cardiovascular eﬀects of
testosterone may be also mediated by adipose tissue, which
embedstheheartandthemostimportantvessels(coronaries,
carotids, aorta, etc.) and is an active site of conversion of
androgens into estrogens, through aromatase activity.
In conclusion, adequate levels and balance of circulating
sex hormones are necessary to maintain a correct distribu-
tion and size of adipose tissue, which in turn is fundamental
to keep a normal reproductive and sexual function. For
this reason, screening of obese patients for hypogonadism
is deemed necessary in order to better understand the
pathophysiology of coexistent metabolic alteration, in order
to target it with a replacement therapy. The delicate issue
of whether testosterone decline, observed with aging, causes
adipose tissue accumulation, or whether weight gain pri-
marily disrupts testicular steroidogenesis, is still unclear and
needs further studies.
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